<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119908</url>
  </required_header>
  <id_info>
    <org_study_id>2019_05</org_study_id>
    <secondary_id>2019-A01601-56</secondary_id>
    <nct_id>NCT04119908</nct_id>
  </id_info>
  <brief_title>Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases</brief_title>
  <acronym>VIDEO-BLEED</acronym>
  <official_title>Interest of Sublingual Videomicroscopy for the Prediction of Bleeding in Von Willebrand Disease and Other Constitutional Haemorrhagic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Willebrand disease, there is currently no test available to identify non-invasively
      patients with a high risk of bleeding from angiodysplasias The study propose to use a
      sublingual capillary bed analysis by video-microscopy, a sensitive, reproducible and
      non-invasive technique, to assess whether sublingual capillary density is predictive of
      hemorrhagic risk for patients with von Willebrand disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the ROC curve from Sublingual capillary density to inclusion for the event &quot;existence of at least a clinically significant haemorrhage&quot;</measure>
    <time_frame>at 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sublingual capillary density</measure>
    <time_frame>At baseline</time_frame>
    <description>To compare the sublingual capillary density of patients with von Willebrand disease to that of 3 other groups of patients:
with a severe form of hemophilia A
with a moderate form of hemophilia A
women carrying the hemophilia gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>qualitative abnormalities of sublingual capillaries (capillary haemorrhage, capillary dystrophy)</measure>
    <time_frame>At baseline and at 3 years</time_frame>
    <description>presence or absence of qualitative abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta of Sublingual capillary density increase</measure>
    <time_frame>between inclusion and end of study (at 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ISTH-BAT haemorrhagic score (International Society on Thrombosis and Hemostasis - Bleeding Assessment Tool)</measure>
    <time_frame>At baseline, at 3 years</time_frame>
    <description>ISTH-BAT is a questionnaire minimum score ranges from 0 to 10 whereas maximum score ranges from 20 to 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta of increase of ISTH-BAT haemorrhagic score</measure>
    <time_frame>between inclusion and end of study (at 3 years)</time_frame>
    <description>ISTH-BAT is a questionnaire minimum score ranges from 0 to 10 whereas maximum score ranges from 20 to 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma levels of proangiogenic markers</measure>
    <time_frame>at inclusion and end-of-study visits(at 3 years)</time_frame>
    <description>dosage of angiopoietin-1, angiopoetin-2 (pg/mL) measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma levels of galectine</measure>
    <time_frame>at inclusion and end-of-study visits(at 3 years)</time_frame>
    <description>galectin-1 and galectin-3 measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma levels of VEGF</measure>
    <time_frame>at inclusion and end-of-study visits(at 3 years)</time_frame>
    <description>Concentration (pg/ml) of Vascular Endothelial Growth Factor (VEGF) in blood measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta of increase in plasma levels of all proangiogenic markers</measure>
    <time_frame>At inclusion and end of study (at 3 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Von Willebrand Diseases</condition>
  <condition>Glanzmann Thrombasthenia</condition>
  <arm_group>
    <arm_group_label>Patients with haemorrhagic disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with von Willebrand disease or Patients with Glanzmann Thrombasthenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with moderate or severe hemophilia A or women carrying the hemophilia gene</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sublingual videomicroscopy</intervention_name>
    <description>Measurement of sublingual capillary density by video microscopy</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Patients with haemorrhagic disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Collection of citrate tubes of 5 mL at baseline and at 36 months</description>
    <arm_group_label>Patients with haemorrhagic disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient with a significant form of von Willebrand disease (according to the
             inclusion criteria of the Willebrand Disease French Reference Center), a Glanzmann
             Thrombasthenia, a moderate to severe Haemophilia A or a woman carrying the hemophilia
             gene

          -  Social insured patient

        Exclusion Criteria:

          -  Minor patient

          -  Refusal of consent

          -  Person benefiting from a system of legal protection

          -  Pregnant patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Rauch, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine Rauch, MD,PhD</last_name>
    <phone>3 20445962 (poste 29673)</phone>
    <phone_ext>+33</phone_ext>
    <email>antoine.rauch@chru-lille.fr</email>
  </overall_contact>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>constitutional haemorrhagic diseases, Videomicroscopy, prediction, bleeding</keyword>
  <keyword>Videomicroscopy</keyword>
  <keyword>prediction</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
    <mesh_term>Thrombasthenia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

